Development, Characterization and Evaluation of Lactoferrin Conjugated and Memantine Loaded Peg-Plga Nanoparticles for the Treatment of Alzheimer's Disease

Rashi Jain, Virendra K. Sharma
2021 Journal of Pharmaceutical Research International  
Alzheimer's disease is a degenerative neurological condition that has no cure and only a few treatment options. It has a negative impact on one's cognitive and behavioural abilities. Traditional medications, such as acetylcholinesterase inhibitors, are often ineffective because they do not penetrate the blood-brain barrier. Targeted therapy strategies involving nanoparticulate drug delivery devices have been employed to improve the efficacy of Alzheimer's disease treatment. Memantine is an
more » ... imer's disease medicine that has been approved for the treatment of mild to moderate symptoms. To boost memantine's action at the target region, we employed a twofold emulsion technique to generate lactoferrin (Lf) combined with biodegradable PEG-PLGA nanoparticles (NPs). The average particle size of the synthesised NPs was 162.60.5 nm, with a polydispersity index of 0.1 and a surface charge of -21.5 mV. The crystalline drug was disseminated within the PLGA matrix, according to the physicochemical characterisation of NPs. During in vitro dissolution studies, the new nanoparticulate formulation displayed a sustained release profile of memantine. The NPs were noncytotoxic to brain cell lines, and bEnd.3 cells had a greater concentration of Lf-NP than unconjugated nanoparticles. The researchers discovered that Lf-conjugated PEG-PLGA nanoparticles carrying memantine are excellent for Alzheimer's disease targeted delivery.
doi:10.9734/jpri/2021/v33i63a36091 fatcat:f5yohp5xlzfa7p4jhnkbyxpjny